Fig. 8: MARV and RAVV mRNA vaccines protect against homologous virus infection in guinea pigs.

Guinea pigs (n = 5 per vaccine) recipients of the MARV mRNA (solid square), RAVV mRNA (solid circle) or mock (n = 5 per virus, square and circle outline) vaccines were challenged with 1,000 PFU of the corresponding guinea pig-adapted MARV (green) or RAVV (blue) by the intraperitoneal route. All animals were monitored for changes in (A) survival, (B) viremia, (C) clinical scores, and (D) % weight change over 28 days. A One RAVV vaccinated guinea pig was euthanized on day 23, due to a sustained physical injury. This animal maintained a steady weight and had no detectable virus during the infection phase and at the time of euthanasia. Two-sided Log-rank Mantel-Cox test for comparison of survival curves from mock and MARV or RAVV mRNA vaccine groups infected with the respective virus. B Serum was collected from all animals over the course of infection and measured for infectious virus by plaque titration (PFU/mL). Limit of detection (LOD). Bar denotes group mean values ± SEM. C, D The outer limits of the box reflect the interquartile range (IQR: Q3–Q1) with median shown as horizontal bars. Whiskers extend to minimum or maximum values.